Compare Definium Therapeutics Inc. Common Shares (DFTX) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs 3M Company — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.73 (market cap $4.59B), while 3M Company trades at $160.41 (market cap $84.36B). The key difference: 3M Company is far larger — about 18.4× Definium Therapeutics Inc. Common Shares's market cap, and 3M Company pays a 1.91% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and 3M Company for 169 Days on average.
| DFTX | MMM | |
|---|---|---|
Market Cap | $4.59B | $84.36B |
Volume | 2,103,937 | 2,325,301 |
Sector | Health | Industrials |
52-Week High | $48.45 | $183.79 |
52-Week Low | $10.68 | $141.10 |
Typical Hold Time | 0 Days | 169 Days |
Enterprise Value | $3.55B | $93.58B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
3M (MMM) trades at $162.12, down 0.93% on the day, with a bearish technical signal and support near $158. The company reported strong Q2 2026 earnings, beating estimates with 5.4% organic growth and a 24.9% adjusted operating margin. Revenue for 2025 was $24.95B with net income of $3.25B, though margins have compressed from prior years. Analysts are mixed with a consensus price target of $191, representing potential upside, but high debt and weak consumer sales pose challenges.
The outlook for MMM is cautiously optimistic amid a genuine turnaround narrative. Investment opportunities include continued operational execution, shareholder returns via dividends and buybacks, and growth in industrial and electronics segments. Key risks involve persistent consumer segment weakness, litigation overhang from PFAS, and macroeconomic pressures affecting demand. The stock's valuation remains elevated with a P/E of 29.06, requiring sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
